Altace Diabetes Complications Claim May Be Discussed By Cmte.
King Pharmaceuticals' proposed claim that Altace reduces complications in diabetes patients receiving the drug to decrease cardiovascular events is likely to be a point of discussion at FDA's Cardio-Renal Drugs Advisory Committee on May 1.
You may also be interested in...
King Pharmaceuticals plans to submit additional data from two studies in support of an Altace effect on diabetes complications.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011